Category Archives: Biotechnology

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Student" conference to their offering. The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference. This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference. The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research. Throughout the course of the four day conference, you will have the opportunity to both network … Continue reading →

The Cerbat Gem Emerald Advisers Inc. PA Acquires New Stake in Puma Biotechnology Inc (PBYI) The Cerbat Gem Puma Biotechnology logo Emerald Advisers Inc. PA bought a new position in shares of Puma Biotechnology Inc (NYSE:PBYI) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 379,289 shares of the ... Digging Up the Facts on Puma Biotechnology, Inc. (PBYI)StockNewsJournal The Puma Biotechnology Inc (PBYI) Upgraded by Zacks Investment Research to BuyBangaloreWeekly Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual MeetingBusiness Wire (press release) Chaffey Breeze -Transcript Daily all 54 news articles » Continue reading here: Emerald Advisers Inc. PA Acquires New Stake in Puma Biotechnology Inc (PBYI) - The Cerbat Gem … Continue reading →

On May 16, 2017, we issued an updated report on Puma Biotechnology, Inc. (PBYI - Free Report) . Puma Biotechnology is a development-stage biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care. The company posted narrower-than-expected loss in the first quarter of 2017. Reported loss of $1.97 per share was also narrower than year-ago figure of $2.19. With no approved products in its portfolio at the moment, the company does not generate revenues yet. The company reported first-quarter results on May 10, 2017. So far this year, Pumas shares have outperformed Zacks classified Medical-Biomed/Genetics industry. The companys shares have gained 4.1% while the industry registered an increase of 2.2%. Puma has made significant progress with its lead candidate, neratinib. The candidate is currently under review in both the U.S. and the EU for HER2+ breast cancer. An approval would be a huge boost for the company given the immense commercial potential in the target market. We note that several additional studies on neratinib targeting different types of breast cancer patient populations are currently underway. During the quarter, Puma presented encouraging data from several ongoing studies on neratinib at the annual meeting of the American … Continue reading →

On May 4, 2017, Puma announced the resignation of its Senior Vice President, Regulatory Affairs, effective as of May 15, 2017, less than two weeks before the FDA's scheduled review of neratinib. On May 5, 2017, Fox Business published an article reporting that a large number of patients taking neratinib suffered from severe side effects, posing a safety risk for the drug. Our investigation concerns whether the Company board of directors has breached its fiduciary duties to shareholders, grossly mismanaged the Company, and/or committed abuses of control in connection with the foregoing. If you own Puma shares and wish to discuss this matter with us, or have any questions concerning your rights and interests with regard to this matter, please contact: Robert I. Harwood, Esq. Benjamin I. Sachs-Michaels, Esq. Harwood Feffer LLP 488 Madison Avenue New York, New York 10022 Phone Numbers: (877) 935-7400 (212)935-7400 Email: bsachsmichaels@hfesq.com Website: http://www.hfesq.com Follow us on Twitter: @HarwoodFeffer Harwood Feffer has been representing individual and institutional investors for many years, serving as lead counsel in numerous cases in federal and state courts. Please visit the Harwood Feffer LLP website (http://www.hfesq.com) for more information about the firm. Attorney Advertising. The law firm responsible for this … Continue reading →

China will evaluate eight pending U.S. agricultural biotechnology product applications by the end of May, potentially opening the door for sales by Dow AgroSciences, DuPont Pioneer, Monsanto, and Syngenta. China agreed to conduct the evaluations as part of an agreement unveiled by the White House on May 12. The two countries reached the trade deal after a meeting in April between U.S. President Donald J. Trump and Chinese President Xi Jinping. U.S. officials have prodded China for years to speed up its lengthy process for deciding whether to approve the import of new genetically modified (GM) crops. It typically takes six years to win Chinese clearance of a GM variety, twice as long as other major nations take. Under the new deal, Chinas National Biosafety Committee will meet by the end of May to assess the safety of eight products made by four major U.S. agrochemical companies. Dow AgroSciences is seeking approval for its corn and soybean seeds, while Syngenta and DuPont Pioneer have each applied to sell a GM corn variety in China. Monsanto makes four of the products pending approval, including herbicide-tolerant corn, soybeans, and two alfalfa varieties that have been under review for nearly six years. The … Continue reading →

The Bucks County commissioners unanimously approved a $2 million state grant that will aid the expansion of the Pennsylvania Biotechnology Center in Buckingham. With their vote Wednesday, the commissioners accepted the agreement between the biotechnology center and the state, and agreed to act as the facilitator for the Redevelopment Assistance Capital Program (RACP). "Every entity that applies for the RACP grant has to have a cooperation agreement with one of the governments to move forward," said Lynn Bush, executive director of the Bucks County Planning Commission. "We are basically the go-between for the company and the state agency." Plans have been in motion for years to add more laboratory and office space to the Biotechnology Center. The state grant and a $4.6 million federal grant will contribute to the overall costs of the project, estimated between $12 million and $13 million. The remainder willbe financed with a conventional loan awarded by Univest Bank. "We're thrilled to continue our partnership with the biotechnology center and allow them the opportunity to grow and expand in that area," said Bucks County Commissioner Robert Loughery. "The center has become a real success story for the county and the region." A groundbreaking ceremony for the … Continue reading →

USA Commerce Daily Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) StockNewsJournal Puma Biotechnology, Inc. (PBYI) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $36.25, up from yesterday's close by 13.46%. Given the stock's recent action ... Reasons to Add Puma Biotechnology (PBYI) to Portfolio Now - NasdaqNasdaq Puma Biotechnology, Inc. (PBYI): Some of the key technical areasUSA Commerce Daily Puma Biotechnology Inc (PBYI) Soars 6.21% on May 18Equities.com TopChronicle -BBNS -PharmiWeb.com (press release) all 28 news articles » Continued here: Digging Up the Facts on Puma Biotechnology, Inc. (PBYI) - StockNewsJournal … Continue reading →

DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Global Biotechnology Congress 2017 - (5th in the Series) Corporate" conference to their offering. The 'Global Biotechnology Congress 2017' would provide eminent scientists the opportunity to present their cutting edge researches in the field of biotechnology and its applications in medicine. A number of Nobel Laureates and leading researchers are expected to participate in this important conference. This unique international conference provides a platform for researchers and decision makers in biotechnology to present their latest findings and learn about all the important developments in biotechnology. Many Nobel Laureates and world's renowned experts will participate in the conference. The conference will cover the translational nature of biotechnological research, with emphasis on both the basic science as well as its applications in industry and academia. Presentations will include major research advances in biotechnology, business development, strategic alliances, partnering trends, product opportunities, growth business models and strategies, licensing and pharmaceutical biotechnology (e.g. vaccines, CNS, cancer, antibodies), medical biotechnology, industrial biotechnology, bioprocess engineering, protein engineering, plant and environmental technologies, transgenic plant and crops, bioremediation, and microbial diversity research. Throughout the course of the four day conference, you will have the opportunity to both network … Continue reading →

Most dynamic stock update: NeoPhotonics Corporation (NPTN), Puma Biotechnology, Inc. (PBYI) The USA Commerce On the close of 05/17/2017 NeoPhotonics Corporation (NYSE:NPTN) dropped -11.07% to hit $8.19. During the session shares stayed in the range from $9.38 to $9.08. RSI( Relative Strength Index) highlights overbought (over 70) and oversold (under 30) ... and more » Continued here: Most dynamic stock update: NeoPhotonics Corporation (NPTN), Puma Biotechnology, Inc. (PBYI) - The USA Commerce … Continue reading →

VANCOUVER, British Columbia--(BUSINESS WIRE)--Novelogics Biotechnology, Inc. announced today that it has entered into a research agreement with The Centre for Drug Research and Development (CDRD), Canadas national drug development and commercialization centre, to further characterize Novelogics' internally-developed antibody immunotherapy for treating cancer. The proprietary technology behind Novelogics innovation involves discovery and development of monoclonal antibodies that target a protein that promotes immune suppression in cancer patients. It is predicted that this new therapy could treat a broad range of cancers, and because it works with the patients own immune system, it would be safer and less toxic with fewer debilitating side-effects. CDRD will be analyzing the technology through custom in vitro assays that will help validate and identify their lead antibody and move it towards a Phase 1 clinical trial as early as 2019. The technology has recently shown preliminary evidence of tumour inhibition in a prostate cancer model and based on results from CDRDs research, it could be expanded to other cancer models. Novelogics President and Chief Scientific Officer Dr. Wayne Cheney stated, We are excited to introduce our novel approach to treating cancer. Unlike other immunotherapies that function by modulating, inhibiting or blocking targets, our innovative drug works … Continue reading →